In 2019, research began with users of anti-diabetes treatment medicines, now study shows side effect could be hair loss

Alopecia or hair loss might be a attainable facet impact of Ozempic-like GLP-1 receptor agonists, significantly semaglutide and tirzepatide, analysis has discovered. The findings, printed in The British Medical Journal, present that GLP-1RA customers had been 37 per cent extra more likely to develop alopecia than SGLT-2 inhibitor customers — diabetes drugs which goal kidneys to take away additional sugar from urine — whereas they’d a 68 per cent increased threat, in comparison with customers of DPP-4 inhibitors.

DPP4-inhibitors are one other class of medication which block the DPP-4 enzyme and stimulate insulin launch. All of the medication are prescribed as anti-diabetes therapies.

Researchers, together with these from the US’ College of Pennsylvania, mentioned that though absolute threat is low, consciousness of the potential impact might assist inform shared remedy selections.

“Use of GLP-1 receptor agonists was related to an elevated threat of non-scarring alopecia (the place hair follicles stay intact, leaving the potential for regrowth) in adults with kind 2 diabetes,” the authors wrote.

Speedy weight reduction is a well known set off of hair shedding and also can result in iron or zinc deficiencies, which disrupt the hair development cycle, they mentioned and added hormonal modifications might also be related.

Nonetheless, additional research are wanted to make clear the underlying mechanisms, the group mentioned.
Digital affected person knowledge from the College of Pennsylvania Well being System (Penn Drugs) was analysed to match charges of alopecia in adults with kind 2 diabetes who began utilizing GLP-1 receptor agonists or different varieties of diabetes medication together with, SGLT-2 inhibitors and DPP-4 inhibitors.Total, 12,004 sufferers utilizing GLP-1 receptor agonists had been in contrast with 15,221 utilizing SGLT-2 inhibitors and an extra 11,964 GLP-1 customers had been in contrast with 11,233 DPP-4 inhibitor customers between January 2019 and September 2024.

The researchers mentioned whereas the research was a rigorous one, primarily based on top quality knowledge from a big consultant cohort, there are limitations.

For instance, an absence of scientific info restricted the group’s capability to evaluate particulars resembling severity, extent, period and reversibility of alopecia after stopping remedy. Nor can the authors rule out the chance that unmeasured elements might have influenced the outcomes.

“Our findings lengthen earlier anecdotal security indicators and supply extra systematic proof to tell scientific consciousness of this potential adversarial impact,” they mentioned.